Zafgen to Present at the JMP Securities Life Sciences Conference
June 13, 2019 16:15 ET
|
Zafgen, Inc.
BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions
June 10, 2019 07:00 ET
|
Zafgen, Inc.
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data...
Zafgen Announces Regulatory Update on ZGN-1061
May 30, 2019 07:00 ET
|
Zafgen, Inc.
Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression...
Zafgen Reports First Quarter 2019 Operating and Financial Results
May 09, 2019 16:15 ET
|
Zafgen, Inc.
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for...
Zafgen to Announce First Quarter 2019 Financial Results
May 02, 2019 16:30 ET
|
Zafgen, Inc.
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2019 16:30 ET
|
Zafgen, Inc.
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to...
Zafgen to Present at the 31st Annual ROTH Conference
March 13, 2019 17:00 ET
|
Zafgen, Inc.
BOSTON, March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
March 11, 2019 16:05 ET
|
Zafgen, Inc.
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258...
Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference
March 07, 2019 08:00 ET
|
Zafgen, Inc.
BOSTON, March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results
March 06, 2019 18:00 ET
|
Zafgen, Inc.
BOSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...